dual glp 1 and gip receptor agonist Targeting GLP-1, & GCG in Obesity Type 2 Diabetes Research Dual and Triple Gut Peptide
Description
hazard ratio 1.60, 95% CI 1.37 to 1.87) but not after confounding factors were accounted for (0.91, 0.73 to 1.12)

In clinical practice, drug selection should therefore prioritize factors such as tolerability, safety profile, adherence, cost, and patient preference rather than expecting major differences in cardiovascular efficacy.

Compare semaglutide, tirzepatide, and retatrutide head to head

More recent evidence is expanding their benefits to heart failure with preserved ejection fraction and clinically important renal outcomes in patients with and without diabetes
Physicians on Sermo share experiences with GLP-1 weight loss drugs and risks
Pricing is for a monthly supply